jetLOGO_edited_edited.png

Clinical trials

David Neskey_edited.jpg

Dr. David Neskey, a head and neck tumor surgeon, performed a checkpoint therapy neoadjuvant clinical trial in oral cavity cancer patients. The trial found that ~30% of patients respond to therapy prior to surgery, demonstrating that checkpoint therapy is a strategy to improve outcomes in oral cavity cancer patients. In collaboration with Dr. Neskey, data from the trial are used in our research group to study why certain patients respond to clinical immunotherapies and some do not. 

Neskey Trial Figure_edited_edited.png
Neskey Trial Figure_edited_edited.png

Clinical concept development

We are currently partnered with surgical and medical oncology to bring our novel combination therapy concept to sarcoma patients. We aim to modulate metabolism within the sarcoma tumor microenvironment in order to invigorate TIL anti-tumor activity. Stay tuned!

ER TR Low-0023 copy.jpg
IL2 Total-0053.jpg
IL15 Total-0029.jpg
ER TR Low-0019 copy.jpg
ER TR High-0009 copy.jpg
ER TR High-0020 copy.jpg
ER TR High-0004 copy.jpg
ER TR Low-0023 copy.jpg
IL2 Total-0053.jpg
IL15 Total-0029.jpg
ER TR Low-0019 copy.jpg
ER TR High-0009 copy.jpg
ER TR High-0020 copy.jpg
ER TR High-0004 copy.jpg
ER TR Low-0023 copy.jpg
IL2 Total-0053.jpg